Anna Maria Di Giacomo

University of Siena — Italy

Medicine · Health Sciences

51h-index14.5kcitations281works5.62yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(174), Immunotherapy and Immune Responses(91), CAR-T cell therapy research(89), Melanoma and MAPK Pathways(52), Cutaneous Melanoma Detection and Management(33)

Publications280 total

Tolerability and Clinical Benefit Assessment of Continuous Roginolisib Administration in Patients with Cancer including Metastatic Uveal Melanoma
2025Open Access
1739eTiP Chemio-immunotherapy in nai¨ve advanced Merkel cell carcinoma (MCC): The phase II PANDORA trial
Annals of Oncology·2025
1621P First-line pembrolizumab alone or with investigational agents for advanced melanoma: Updated results from the phase I/II KEYMAKER-U02 substudy 02B
Annals of Oncology·2025
1609P Final, 9-year results from the CheckMate 238 phase III trial of adjuvant nivolumab vs ipilimumab in resected stage IIIB–C or IV melanoma
Annals of Oncology·2025· 1 citedOpen Access
1640P ADU-1604, a differentiated CTLA-4 blocking antibody shows benchmark clinical efficacy with a milder safety profile in PD1 relapse/refractory melanoma patients
Annals of Oncology·2025
Biomolecular Predictors of Recurrence Patterns and Survival in IDH-Wild-Type Glioblastoma: A Retrospective Analysis of Patients Treated with Radiotherapy and Temozolomide
Brain Sciences·2025· 2 citedOpen Access
The phase II NIBIT-ML1 study of nivolumab plus ipilimumab and ASTX727 or nivolumab plus ipilimumab in PD-1 resistant metastatic melanoma: Tumor methylation landscape and correlation with clinical outcomes.
Journal of Clinical Oncology·2025
TeLuRide-006: An adaptive phase 2/3 study of EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, in combination with pembrolizumab in patients with advanced melanoma.
Journal of Clinical Oncology·2025
Tebentafusp in metastatic uveal melanoma patients: Results of the Italian expanded access program.
Journal of Clinical Oncology·2025· 1 cited
Abstract 4841: DNA methylation status classifies pleural mesothelioma cells according to their immune profile: implication for precision epigenetic therapy
Cancer Research·2025
DNA methylation status classifies pleural mesothelioma cells according to their immune profile: implication for precision epigenetic therapy
Journal of Experimental & Clinical Cancer Research·2025· 2 citedOpen Access
Immunotherapy or targeted therapy with or without stereotactic radiosurgery for patients with brain metastases from melanoma or non-small cell lung cancer – The ETOP 19-21 USZ-STRIKE study
Lung Cancer·2024· 4 citedOpen Access
164P Roginolisib (IOA-244), the first highly selective oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ), has immuno-modulatory effects associated with clinical benefits in patients with metastatic uveal melanoma
Immuno-Oncology Technology·2024· 1 citedOpen Access
41P Total tumor burden and radiomics to evaluate response in dose escalation studies: Roginolisib (IOA-244), a highly selective PI3Kδ inhibitor in metastatic uveal melanoma patients
Immuno-Oncology Technology·2024Open Access
131 Baseline and early follow-up radiomics biomarkers for tumor growth in uveal melanoma patients treated with roginolisib (IOA-244)
Regular and Young Investigator Award Abstracts·2024Open Access
626P Roginolisib (IOA-244), a first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) in patients with metastatic uveal melanoma
Annals of Oncology·2024Open Access
1916P Methylation subtypes correlate with tumor immune contextures and outcome to ICI therapy of pleural mesothelioma (PM) patients: The NIBIT EPI-MESO study
Annals of Oncology·2024· 1 citedOpen Access
1083P KEYMAKER 02B: A randomized trial of pembrolizumab (pembro) alone or with investigational agents as first-line treatment for advanced melanoma
Annals of Oncology·2024· 2 citedOpen Access
LBA47 Nivolumab plus ipilimumab and ASTX727 or nivolumab plus ipilimumab in PD-1 resistant metastatic melanoma: Primary analysis of the randomized phase II NIBIT-ML1 study
Annals of Oncology·2024· 3 citedOpen Access
DNA methylation status classifies pleural mesothelioma cells according to their immune profile: implication for precision epigenetic therapy
2024Open Access
page 1 of 14Next →

Frequent Co-authors

Michele Maio(31), Paolo A. Ascierto(24), Dirk Schadendorf(19), Paola Queirolo(14), Mario Mandalà(13), Piotr Rutkowski(13), Luana Calabrò(13), Riccardo Danielli(13), Victoria Atkinson(12), Georgina V. Long(11), Vanna Chiarion‐Sileni(11), Diana Giannarelli(11), Maresa Altomonte(11), Claus Garbe(9), Ralf Gutzmer(9), Christian U. Blank(9), Stéphane Dalle(9), Caroline Robert(9), James Larkin(8), Jessica C. Hassel(8)